Skip to content
Subscriber Only

Pfizer’s Miss on AstraZeneca May Put Breakup Back in Play

With prospects for an AstraZeneca Plc deal falling apart, Pfizer Inc. Chief Executive Officer Ian Read is facing a new question from investors: What now?

There aren’t other ripe targets offering the triple benefits of a lower tax rate in the U.K., cost savings and new cancer drugs, analysts say. Without AstraZeneca’s promise of new growth, Read, 60, will likely return to an earlier plan to further break up what was once the world’s biggest drugmaker.